Your browser doesn't support javascript.
loading
Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease: A Multicenter Study.
Khor, Yet H; Farooqi, Malik; Hambly, Nathan; Johannson, Kerri A; Marcoux, Veronica; Fisher, Jolene H; Assayag, Deborah; Manganas, Helene; Khalil, Nasreen; Kolb, Martin; Ryerson, Christopher J.
Afiliação
  • Khor YH; Department of Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, VIC, Australia; Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, VIC, Australia; Institute for Breathing and Sleep, Heidelberg, VIC, Australia; Department of Respiratory Medicine
  • Farooqi M; Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
  • Hambly N; Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
  • Johannson KA; Department of Medicine, University of Calgary, Calgary, AB, Canada.
  • Marcoux V; Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
  • Fisher JH; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Assayag D; Department of Medicine, McGill University, Montreal, QC, Canada.
  • Manganas H; Département de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
  • Khalil N; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Kolb M; Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
  • Ryerson CJ; Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada.
Chest ; 163(2): 345-357, 2023 02.
Article em En | MEDLINE | ID: mdl-36089070
ABSTRACT

BACKGROUND:

Functional capacity, as measured by the 6-min walk test (6MWT), is often reduced in fibrotic interstitial lung disease (ILD). This study evaluated longitudinal changes and the prognostic significance of 6MWT parameters, and explored change in oxygenation status as a physiological criterion to define disease progression in patients with fibrotic ILD. RESEARCH QUESTIONS What are the trajectories and prognostic value of 6MWT parameters in patients with fibrotic ILD? STUDY DESIGN AND

METHODS:

Using prospective registries in Australia and Canada, patients with idiopathic pulmonary fibrosis (IPF) and non-IPF fibrotic ILD were stratified by the presence of criteria for progressive pulmonary fibrosis (PPF). The cumulative incidence of exertional and resting hypoxemia and changes in 6-min walk distance (6MWD) and composite indices (distance-saturation product and distance-saturation-oxygen product) were determined, with prognostic significance evaluated at the time of meeting criteria for PPF. New-onset exertional or resting hypoxemia was evaluated as another potential criterion for PPF.

RESULTS:

Patients with IPF/PPF (n = 126) and non-IPF/PPF (n = 227) had a similar cumulative incidence of exertional hypoxemia and annualized decline in 6MWD and composite indices, which varied across each PPF criterion. Patients with IPF/non-PPF (n = 231) and non-IPF/non-PPF (n = 531) had a significantly lower incidence of hypoxemia than those with IPF/PPF, with an annualized increase in 6MWD and composite indices in the non-IPF/non-PPF group. Exertional or resting hypoxemia at the time of meeting criteria for PPF was independently associated with reduced transplant-free survival in IPF and non-IPF, adjusting for patient demographics and lung function. Adding new-onset exertional or resting hypoxemia as a physiological criterion reduced the median time to development of PPF from 11.2 to 6.7 months in IPF and from 11.7 to 5.6 months in non-IPF in patients who eventually met both definitions (P < .001 for both).

INTERPRETATION:

Patients with IPF/PPF and non-IPF/PPF have comparable deterioration in functional capacity. Oxygenation status provides prognostic information in PPF and may assist in defining disease progression in fibrotic ILD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Pulmonares Intersticiais / Fibrose Pulmonar Idiopática Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Chest Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Pulmonares Intersticiais / Fibrose Pulmonar Idiopática Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Chest Ano de publicação: 2023 Tipo de documento: Article